These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11585344)

  • 41. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1.
    Garcia-Palacios V; Chung HY; Choi SJ; Sarmasik A; Kurihara N; Lee JW; Galson DL; Collins R; Roodman GD
    Bone; 2007 Feb; 40(2):316-22. PubMed ID: 16996813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
    Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
    Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
    Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
    J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
    Tian QX; Huang GY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.
    Han JH; Choi SJ; Kurihara N; Koide M; Oba Y; Roodman GD
    Blood; 2001 Jun; 97(11):3349-53. PubMed ID: 11369623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
    Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
    Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease.
    Ishizuka S; Kurihara N; Reddy SV; Cornish J; Cundy T; Roodman GD
    Endocrinology; 2005 Apr; 146(4):2023-30. PubMed ID: 15618361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice.
    Sakai A; Nishida S; Nishida S; Tsutsui T; Takeuchi K; Takeda S; Nakamura T
    J Bone Miner Metab; 2001; 19(5):277-86. PubMed ID: 11498729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
    Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA
    Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of Regulatory Extracellular Vesicles from Osteoclasts.
    Huynh N; VonMoss L; Smith D; Rahman I; Felemban MF; Zuo J; Rody WJ; McHugh KP; Holliday LS
    J Dent Res; 2016 Jun; 95(6):673-9. PubMed ID: 26908631
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors.
    Shin MM; Kim YH; Kim SN; Kim GS; Baek JH
    Exp Mol Med; 2003 Jun; 35(3):167-74. PubMed ID: 12858015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
    Sugatani T; Alvarez UM; Hruska KA
    J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Osteoclastogenesis is decreased by cysteine proteinase inhibitors.
    Brage M; Lie A; Ransjö M; Kasprzykowski F; Kasprzykowska R; Abrahamson M; Grubb A; Lerner UH
    Bone; 2004 Mar; 34(3):412-24. PubMed ID: 15003789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.